Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-5112PMID 18829516
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute drug induced hepatitis due to erlotinib.

  2007cited by this paper
• Risk of acute liver injury associated with the use of drugs: a multicentre population survey

  2007cited by this paper
• Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix?

  2007cited by this paper
• The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy.

  2007cited by this paper
• EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.

  2007cited by this paper
• Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer).

  2006cited by this paper
• Phase I study of erlotinib (E) for solid tumors in patients with hepatic or renal dysfunction (HD or RD): CALGB 60101.

  2006cited by this paper
• Phase II study of erlotinib in patients with advanced biliary cancer.

  2006cited by this paper
• Practical management of patients with non-small-cell lung cancer treated with gefitinib.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)

  2005cited by this paper
• Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix.

  2005cited by this paper
• Erlotinib as a Radiosensitizer for Patients with Esophageal Cancer

  2005cited by this paper
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  2004cited by this paper
• [Anti-EGFR and radiotherapy].

  2004cited by this paper
• Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.

  2004cited by this paper
• Anti-REGF et radiothérapie

  2004cited by this paper
• Prognostic factors for low-grade gliomas.

  2003cited by this paper
• Development of the epidermal growth factor receptor inhibitor OSI-774.

  2003cited by this paper
• Dermatologic side effects associated with gefitinib therapy: clinical experience and management.

  2003cited by this paper
• Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: an update of RTOG 90–01

  2002cited by this paper
• Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix

  2002cited by this paper
• Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix.

  2002cited by this paper
• Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

  2000cited by this paper
• In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.

  2000cited by this paper
• Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.

  1999cited by this paper
• Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

  1999cited by this paper
• Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

  1999cited by this paper
• Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.

  1999cited by this paper
• Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

  1997cited by this paper
• Induction chemotherapy and radiotherapy of advanced cancer of the cervix: a pilot study and phase III randomized trial.

  1997cited by this paper
• [Growth factors and cancer].

  1994cited by this paper
• Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study.

  1994cited by this paper
• Hepatotoxicity Associated with Cisplatin Chemotherapy

  1993cited by this paper
• Experience with bleomycin, ifosfamide, and cisplatin in primary and recurrent cervical cancer.

  1992cited by this paper
• Ondansetron metabolism and pharmacokinetics.

  1992cited by this paper
• Growth factors and cancer.

  1991cited by this paper
• Phénomène de Raynaud après chimiothérapie. A propos de 3 observations

  1985cited by this paper
• [Raynaud's phenomenon after chemotherapy. Apropos of 3 cases].

  1985cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper

• PET for predicting chemoradiotherapy survival in cervical cancer: the search continues.

  2025cites this paper
• New Investigational Drug’s Targeting Various Molecular Pathways for Treatment of Cervical Cancer: Current Status and Future Prospects

  2024cites this paper
• An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer

  2022cites this paper
• A review on the role of epidermal growth factor signaling in the development, progression and treatment of cervical cancer.

  2021cites this paper
• The Comparative Studyin Locally Advanced Carcinoma Cervix with Radiotherapy and Concurrent Weekly Cisplatin versus Concurrent Daily Erlotinib & Weekly Cisplatin An Extended Follow Up Study

  2018influential citation
• Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells

  2018cites this paper
• Comparative Evaluation of Radiotherapy with Concurrent Weekly Cisplatin versus Concurrent Daily Erlotinib and Weekly Cisplatin in Locally Advanced Carcinoma Cervix

  2018influential citation
• Adenocarcinoma histology is a poor prognostic factor in locally advanced cervical cancer

  2018cites this paper
• Investigational drugs for the treatment of cervical cancer

  2017cites this paper
• A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I

  2016cites this paper
• Novel agents and treatment techniques to enhance radiotherapeutic outcomes in carcinoma of the uterine cervix.

  2016cites this paper
• Signaling pathways in HPV‐associated cancers and therapeutic implications

  2015cites this paper
• Emerging drugs for the treatment of cervical cancer

  2015cites this paper
• Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines

  2015cites this paper
• Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer

  2014influential citation
• New molecular targets against cervical cancer

  2014cites this paper
• Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer

  2014cites this paper
• 10 New Therapeutic Targets

  2014cites this paper
• The role of signaling pathways in cervical cancer and molecular therapeutic targets.

  2014cites this paper
• Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials.

  2014cites this paper
• Cervical cancer: are there potential new targets? An update on preclinical and clinical results.

  2014cites this paper
• Concurrent chemoradiation for carcinoma of cervix: what lies beyond?

  2014cites this paper
• effec-Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer

  2014cites this paper
• Phase 1 study of cetuximab in combination with 5‐fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma

  2013cites this paper
• Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non-Platinum-Containing Regimens, and Molecular Targeted Agents

  2013cites this paper
• Topotecan Use for Second-Line Treatment in Patients with Recurrent or Metastatic Cervical Cancer at Brazilian National Cancer Institute (INCA) *

  2013cites this paper
• 18F-FDG-PET-based tumor delineation in cervical cancer: threshold contouring and lesion volumes.

  2013cites this paper
• Prognostic value of microvascular density and expression of VEGF, EGFR and HIF-1α in patients with locally advanced cervical cancer treated with chemoradiation (ONCOLGroup)§

  2012cites this paper
• Predictors of Cervical Cancer Screening: An Application of Health Belief Model

  2012cites this paper
• A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.

  2012cites this paper
• Emerging drugs for cervical cancer

  2012cites this paper
• New Therapeutic Targets

  2012cites this paper
• Topics on Cervical Cancer With an Advocacy for Prevention

  2012cites this paper
• Molecularly targeted therapies in cervical cancer. A systematic review.

  2012cites this paper
• Epidermal growth factor receptor as a biomarker for cervical cancer.

  2011cites this paper
• Recent Advances in Anti-Angiogenic Therapy of Cancer

  2011cites this paper
• Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16.

  2011cites this paper
• Radiotherapy and "new" drugs-new side effects?

  2011cites this paper
• The Development of Priority Cervical Cancer Trials: A Gynecologic Cancer InterGroup Report

  2010cites this paper
• Pharmacotherapy Options for Locally Advanced and Advanced Cervical Cancer

  2010cites this paper
• Frequent Deregulations in the Hedgehog Signaling Network and Cross-Talks with the Epidermal Growth Factor Receptor Pathway Involved in Cancer Progression and Targeted Therapies

  2010cites this paper
• Locally advanced cervical cancer: what is the standard of care?

  2010cites this paper
• Targeting EGFR in HPV-Associated Cancer

  2010cites this paper
• Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.

  2010cites this paper
• Emerging therapeutic agents for cervical cancer.

  2009cites this paper
• Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors

  2009cites this paper
• Strahlenbiologie: Hypofraktionierung und kombinierte Therapien

  2009cites this paper
• Receptor tyrosine kinase inhibitors as potent weapons in war against cancers.

  2009cites this paper
• Estudo de fase I/II de Erlotinib (OZI-774) combinado com radioterapia e cisplatina em pacientes com carcinoma epidermóide de cabeça e pescoço, localmente avançado

  2009cites this paper
• Current world literature.

  2005cites this paper